Effects of galantamine on smoking behavior and cognitive performance in treatment-seeking smokers prior to a quit attempt.

ABSTRACT:

Objective

Drugs that enhance cholinergic transmission have demonstrated promise treating addictive disorders. Galantamine, an acetylcholinesterase inhibitor, may reduce cigarette smoking in otherwise healthy treatment-seeking smokers.

Methods

The current study is a double-blind, placebo-controlled, study that randomized daily smokers (n = 60) to receive one of two doses of galantamine extended release (8 or 16 mg/day), or a placebo treatment. Participants completed a smoking choice task as well as study measures and cognitive tasks in the laboratory and daily life using ecological momentary assessment. Analysis focused on smoking behavior and satisfaction, cognitive performance, and decision to smoke prior to a quit attempt.

Results

Linear mixed models demonstrated th

SUBMITTER: MacLean RR 

PROVIDER: S-EPMC6168949 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature